| Assessment Status | Rapid Review Complete |
| HTA ID | 24029 |
| Drug | Olaparib |
| Brand | Lynparza® |
| Indication | Olaparib (Lynparza®) is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen |
| Assessment Process | |
| Rapid review commissioned | 17/07/2024 |
| Rapid review completed | 13/08/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib for this indication compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
